Shopping Cart
Remove All
Your shopping cart is currently empty
Camidanlumab tesirine
😃Good
Catalog No. T9901A-964Cas No. 1853239-04-9
Alias ADCT 301
Camidanlumab tesirine (ADCT 301) is an ADC consisting of a human IgG1 antibody, HuMax-TAC, targeting CD25, which is conjugated through a dipeptide-cleavable linker to pyrrolobenzodiazepine (PBD) dimer payloads. The drug-antibody ratio (DAR) of Camidanlumab tesirine is 2.3. It binds to human CD25 with picomolar affinity and exhibits potent and selective cytotoxicity against human lymphoma cell lines expressing CD25.
Camidanlumab tesirine
Camidanlumab tesirine
😃Good
Catalog No. T9901A-964Alias ADCT 301Cas No. 1853239-04-9
Camidanlumab tesirine (ADCT 301) is an ADC consisting of a human IgG1 antibody, HuMax-TAC, targeting CD25, which is conjugated through a dipeptide-cleavable linker to pyrrolobenzodiazepine (PBD) dimer payloads. The drug-antibody ratio (DAR) of Camidanlumab tesirine is 2.3. It binds to human CD25 with picomolar affinity and exhibits potent and selective cytotoxicity against human lymphoma cell lines expressing CD25.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | Inquiry | Inquiry | Inquiry | |
| 5 mg | Inquiry | Inquiry | Inquiry |
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Resource Download
Product Introduction
Bioactivity
Antigen Details
Chemical Properties
Storage & Solubility Information
| Description | Camidanlumab tesirine (ADCT 301) is an ADC consisting of a human IgG1 antibody, HuMax-TAC, targeting CD25, which is conjugated through a dipeptide-cleavable linker to pyrrolobenzodiazepine (PBD) dimer payloads. The drug-antibody ratio (DAR) of Camidanlumab tesirine is 2.3. It binds to human CD25 with picomolar affinity and exhibits potent and selective cytotoxicity against human lymphoma cell lines expressing CD25. |
| In vitro | Camidanlumab tesirine (ADCT 301; 3, 10 ng/mL; 48 h) causes dose-dependent G2-M phase arrest, peaking at 48 hours. It (10 ng/mL; 24-96 h) induces apoptosis. The compound exhibits a GI50 range of 0.04-2.94 ng/mL in CD25 positive cell lines, but >1,000 ng/mL in CD25 negative cell lines. In both antigen-expressing and non-expressing cell lines, for the unconjugated ADC, the GI50 value is >1,000 ng/mL. |
| In vivo | Camidanlumab tesirine (ADCT 301; 0.1-0.6 mg/kg/day;Intravenous injection; 60 days) inhibits tumor growth in a dose-dependent manner. Its half-life, calculated through analysis of the bound antibody with a DAR component ≥1, is 7.3 days. |
| Synonyms | ADCT 301 |
| Reactivity | Human |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Endotoxin | ＜ 1.0 EU/mg |
| Target | CD25 |
| Cas No. | 1853239-04-9 |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy Camidanlumab tesirine | purchase Camidanlumab tesirine | Camidanlumab tesirine cost | order Camidanlumab tesirine | Camidanlumab tesirine in vivo | Camidanlumab tesirine in vitro
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.